Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Immunoglobulins Market - Outlook and Forecast 2021-2026
The Immunoglobulins Market, valued at USD 13.5 billion in 2020, is projected to reach USD 21.58 billion by 2026, exhibiting a CAGR of 8.01% from 2022 to 2027. Immunoglobulins, produced by plasma cells as part of the body’s immune system, are glycoprotein molecules that are secreted in response to antigens entering the body. The ongoing pandemic has significantly impacted the plasma derivatives industry. It has led to an increase in the cost per liter of collected plasma due to higher donor fees and fixed costs for centers despite lower volumes collected. However, recent advancements and the expanding applications of immunoglobulin products in treating rare and autoimmune diseases have contributed to the market’s growth.
In Europe, the price of immunoglobulin has risen by approximately 5%, while in the US, it has increased by 6%. Technological and scientific developments in plasma fractionation, driven by the growing outcome of fractionation and the challenge of plasma shortage, are expected to propel the market forward. Immunoglobulins currently dominate the plasma-derived products industry, primarily due to the increasing demand resulting from improved methods of diagnosing autoimmune diseases.
|No. of Pages||
USD 13.6 billion in 2019
Product, Application, End-User, and Geography
|No. of Companies Mentioned||
One of the main challenges faced by the industry is maintaining a balance between supply and demand. As the production of immunoglobulin products relies on blood plasma, the quantity of plasma collected limits their production capacity. Many vendors have experienced growth through partnerships with official plasma collection agencies in their respective countries.
The market is segmented based on various factors, including product, application, end-user, and geography.
Segmentation By Product
Segmentation By Application
Chronic Immune Deficiency Polyradiculoneuropathy
Immune Thrombocytopenic Purpura
By End User
Hospital & Clinic
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey
In the management of autoimmune diseases and immunodeficiency, intravenous immunoglobulins (IVIG) are commonly used. This therapeutic approach involves administering immunoglobulins through the intravenous route, which ensures maximum bioavailability and efficacy.
Primary immunodeficiency accounted for 26.05% of the global immunoglobulins market in 2020, making it the leading segment. Symptoms of primary immunodeficiencies include recurring pneumonia, respiratory infections, sinus infections, skin infections, meningitis, inflammation, and low platelet count, among others.
Hospitals and clinics represent the largest end-user segment in the immunoglobulins market, holding a significant market share. However, the home care segment is expected to witness faster growth due to increasing demand for home healthcare services.
In 2020, North America held a substantial share of 46.00% in the global immunoglobulins market. This can be attributed to several factors, including heightened personal health awareness, a patient-centric healthcare system, advancements in healthcare infrastructure, a robust network of plasma collection centers, and the presence of leading global vendors native to the industry.
Europe stands as the second-largest market for immunoglobulin products, driven by its high demand compared to other regions. The region boasts a well-regulated market and a strong awareness of safe blood and plasma collection practices.
The Asia-Pacific (APAC) region is an emerging market for immunoglobulin products, particularly for the treatment of autoimmune disorders. China leads the APAC immunoglobulins market, benefitting from a population that is highly aware of blood donation and its potential use in manufacturing life-saving products.
The industry is primarily led by three key vendors, namely CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A. These vendors operate in a highly competitive environment where they strive to gain an edge through the introduction of new products and obtaining regulatory approvals for both new and existing products.
For new entrants in the market, emerging markets and low-resource countries present ideal opportunities. These markets have larger populations and a greater willingness among individuals to donate blood or plasma in exchange for compensation.
For vendors operating in this industry, the procurement of plasma for fractionation is a critical factor. To address this, many vendors have established extensive networks of plasma collection centers across various countries, enabling them to collect larger volumes of plasma.
The growth of numerous vendors has been significantly driven by partnerships with official plasma collection agencies in different countries. Such partnerships have provided new vendors with valuable opportunities for growth and expansion.
Key companies profiled in this report include Takeda Pharmaceutical Company Limited, CSL Limited, Grifols, S.A, Kendrion Biopharma, Octapharma AG., China Biologic Products Holding, Inc., Biotest AG, LFB S.A., ADMA Biologics, Inc., Omrix Biopharmaceuticals LTD, Zydus Cadila, Bharat Serums and Vaccines Limited, Reliance Life Sciences.
Key Questions Answered
What is the size of the immunoglobulins market?
The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is projected to reach USD 21.58 billion by 2026.
What are the main trends in the immunoglobulins market?
The main trends in the immunoglobulins market include advancements in the plasma fractionation process, growing utilization of immunoglobulins in homecare settings, and recent regulatory approvals for immunoglobulin therapies.
Which region holds the largest market share in the immunoglobulins market?
North America region holds the largest market share in the immunoglobulins market.
Who are the major players in the immunoglobulins market?
The major players in the immunoglobulins market are Takeda Pharmaceutical, CSL Limited, Grifols, S.A., Kendrion Biopharma, and Octapharma AG.
What are the factors propelling the growth of the immunoglobulins market?
The factors driving the growth of the immunoglobulins market include the impact of intravenous immunoglobulin (IVIg) usage in transplant procedures and the implementation of self-sufficiency programs for plasma-derived medicinal products.